Table 1. Gene alterations in thymic epithelial tumors (TETs) with a frequency >1.5%. The data are retrieved from the cBioPortal for Cancer Genomics (18,19) and encompass the study cohorts of (6,7).
| Gene | TET (n=155*), % | WHO subtypes, % | |||||
|---|---|---|---|---|---|---|---|
| Type A (n=24) | Type AB (n=39) | Type B1 (n=15) | Type B2 (n=33) | Type B3 (n=20) | TC (n=23) | ||
| GTF2I | 43.0 | 87.5 | 76.9 | 20 | 21.2 | 15 | 8.7 |
| HRAS | 7.0 | 29.2 | 7.7 | – | – | – | 4.3 |
| TP53 | 5.0 | 4.2 | – | – | 3 | 5 | 21.7 |
| CYLD | 3.0 | – | – | – | – | – | 21.7 |
| PCLO | 3.0 | 4.2 | 5.1 | – | – | – | 8.7 |
| HDAC4 | 3.0 | 4.2 | 5.1 | – | – | 5 | 4.3 |
| BCOR | 2.6 | 4.2 | – | – | 9 | – | – |
| PBRM1 | 2.6 | – | 2.6 | – | – | – | 13.0 |
| BRD4 | 2.6 | – | – | – | 3 | – | 13.0 |
| CSF1R | 1.9 | 4.2 | – | – | 3 | – | 4.3 |
| FGF3 | 1.9 | 4.2 | – | – | 3 | – | 4.3 |
| NRAS | 1.9 | 4.2 | – | – | 3 | – | 4.3 |
| PAX7 | 1.9 | 4.2 | – | – | – | – | 8.7 |
| PTPRB | 1.9 | 4.2 | 2.6 | – | 3 | – | – |
| ZMYM3 | 1.9 | – | 2.6 | – | 6 | – | – |
| NOD1 | 1.9 | 4.2 | 2.6 | – | – | – | 4.3 |
*, 1 TET sample not otherwise specified; TC, thymic carcinoma.